Pavurutamab - CAS 2250292-39-6

Pavurutamab (AMG-701) is a bispecific T-cell engager targeting CD3 and B-cell maturation antigens (BCMA), with an extended half-life derived from Pacanalotamab. Its Fc region is engineered for improved pharmacokinetics, offering potential in immune regulation and treatment of multiple myeloma (MM) [1] [2] [3] [4].

Integrin

Cytoskeletal Signaling

2250247

-20°C

Ice Packs

Inhibitory Antibodies